Related Experiment Video
Updated: Aug 7, 2025
04:16
Intraoperative Visualization of Subretinal Injection and Retinal Detachment in Rats
Published on: March 7, 2025
537
EXUDATIVE RETINAL DETACHMENT AFTER INTRAVITREAL BROLUCIZUMAB INJECTION
Devin M Betsch1, David Sarraf2, Carolina L M Francisconi1
1Department of Ophthalmology & Visual Sciences, Dalhousie University, Halifax, Canada; and.
Retinal Cases & Brief Reports
|March 9, 2023
Summary
A patient developed severe intraocular inflammation and exudative retinal detachment after a brolucizumab injection for wet age-related macular degeneration. This case highlights the need for vigilance with new treatments.
Area of Science:
- Ophthalmology
- Retinal diseases
- Pharmacology
Background:
- Neovascular age-related macular degeneration (nAMD) is a leading cause of vision loss.
- Brolucizumab is a newer intravitreal treatment option for nAMD.
- Intraocular inflammation (IOI) has been reported with brolucizumab therapy.
Observation:
- An 80-year-old woman with nAMD developed severe IOI and exudative retinal detachment 11 days post-first brolucizumab injection.
- The patient was treated with systemic and topical steroids.
- Optical coherence tomography and ultra-widefield fluorescein angiography documented the condition.
Findings:
- The patient's IOI and exudative retinal detachment resolved within three weeks of treatment.
- Literature suggests a higher incidence of IOI with brolucizumab compared to aflibercept.
- Recent reports indicate severe IOI and retinal vasculitis associated with brolucizumab.
Implications:
- This is the first reported case of exudative retinal detachment following intravitreal brolucizumab.
- Increased reporting of such events is crucial for understanding and developing management strategies.
- Continued surveillance is necessary to ensure patient safety and optimize outcomes with brolucizumab therapy.
